Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
SAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the closing of a $66 million Series B financing. New investor Regeneron Ventures and current investor Deerfield Management co-led the financing, with participation from existing investors Canaan, Droia Ventures and Euclidean Capital.
Actio's pipeline is led by ABS-1230, a KCNT1 inhibitor for the treatment of KCNT1-related epilepsy and other genetic epilepsies, and ABS-0871, a TRPV4 inhibitor currently being evaluated in a Phase 1 healthy volunteer clinical trial for the treatment of Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder.
'We have made tremendous progress across our pipeline – executing a precision medicine strategy that targets the root causes of disease through genetically informed drug development,' said David Goldstein, Ph.D., co-founder and CEO of Actio. 'ABS-1230 and ABS-0871 have the potential to be transformative disease-modifying therapies in their respective rare indications and growing evidence supports expansion into broader indications. This new funding from industry-leading investors speaks to the value of our approach and provides us with important resources to continue advancing our programs.'
The Series B financing will support the advancement of Actio's lead programs, ABS-1230 and ABS-0871.
ABS-1230 is a potential first-in-class oral, selective small molecule KCNT1 inhibitor for the treatment of KCNT1-related epilepsy, a rare and often fatal pediatric epileptic encephalopathy with a United States (U.S.) prevalence of approximately 2,500 individuals. In preclinical studies, ABS-1230 has been shown to inhibit all recurrently observed pathogenic mutations in the KCNT1 gene, making ABS-1230 broadly applicable to patients with KCNT1-positive epilepsy. Actio plans to initiate the healthy volunteer portion of a Phase 1 clinical trial of ABS-1230 in the second half of 2025 with plans to expand into a proof-of-concept Phase 1b study in KCNT1-related epilepsy patients in early 2026. ABS-1230 was recently granted both rare pediatric and orphan drug designations from the U.S. Food and Drug Administration (FDA).
ABS-0871 is a potential first-in-class oral, small molecule TRPV4 inhibitor for the treatment of CMT2C, a rare inherited disorder that affects both motor and sensory functions with a U.S. prevalence of approximately 2,500 individuals. Preclinical evaluation of this program in novel construct valid CMT2C rare disease models has demonstrated marked improvements in motor function and mobility, compared to untreated controls. Given its mechanism of action targeting TRPV4, ABS-0871 may also have therapeutic potential for the treatment of overactive bladder. Actio is currently advancing ABS-0871 in the healthy volunteer portion of a Phase 1 clinical trial with plans to expand into a Phase 1b study in patients with TRPV4+ CMT2C in 2026. ABS-0871 was granted rare pediatric drug, orphan drug and fast track designations from the FDA.
'Actio has done an exceptional job of identifying serious unmet needs in rare disease and advancing solutions that may also be applicable to patients with more common diseases,' said Jason Fuller, Ph.D., Partner, Deerfield Management. 'We're pleased to support the company, encouraged by its progress, and excited by the team's potential to make a difference for patients.'
About Actio Biosciences
Actio Biosciences is a clinical-stage company leveraging advances in precision medicine to develop new therapeutics that target shared genetics in rare and common diseases—bringing meaningful medicines from one to many. Applying its expertise in genetics, drug discovery and data sciences, Actio seeks to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics. Actio is advancing two lead rare disease programs – ABS-0871 and ABS-1230 – with first-in-class potential for the treatment of Charcot-Marie-Tooth disease, type 2C (CMT2C) and KCNT1-related epilepsy, respectively. Founded in October 2021, the San Diego-based company is guided by leaders in genetics and drug development and backed by top healthcare investors. For more information, please visit ActioBiosciences.com and follow the company on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Eutelsat and France's Armed Forces Ministry Reach Landmark Framework Agreement for Low Orbit Satellite Services in the Context of Frances' NEXUS Program
Signaling a strategic evolution in France's space strategy, combining military and civilian resources Underscoring the crucial role of low Earth orbit (LEO) constellations in defense applications Providing strategic in-space resources in advance of the availability of the IRIS² constellation PARIS, June 18, 2025--(BUSINESS WIRE)--Regulatory News: Eutelsat (ISIN: FR0010221234 - Euronext Paris / London Stock Exchange: ETL) and France's armed forces ministry (Direction générale de l'armement) have today announced a landmark framework agreement on the occasion of the Paris Airshow. The agreement is the embodiment of the NEXUS (Neo-Espace pour de multiples Usages Sécurisés) program launched by the French Ministry of Defence, which aims to reinforce the current French military space communications model by combining military and civilian resources. France reaffirms its commitment to the European IRIS² program, which has been supported from the outset since the French Presidency of the Council of the European Union in 2022. However, the urgency of the international situation means that it cannot wait until then. As the first concrete step in the NEXUS project, the French defense procurement agency (DGA) has reached a 10-year framework agreement, valued at up to €1 billion in expenditure, with Eutelsat, covering the supply of priority-access space resources (notably capacity on Eutelsat's OneWeb LEO constellation), the hosting of ancillary missions for the French armed forces, and operational and security maintenance. The agreement also covers the upgrading and securing of the constellation for military grade use. Jean-Francois Fallacher, Chief Executive Officer of Eutelsat commented: "We are honored at the prospect of supporting the French armed forces through this historic agreement, which underscores the crucial role of low earth orbit satellite capacity in responding to the requirements of contemporary operational theaters. Eutelsat today offers the only commercially operated LEO constellation capable of meeting stringent military standards ahead of the deployment of IRIS². It provides global coverage, low latency, rapid deployment, and adaptability to mobile use cases, attributes validated by successful large-scale experiments conducted with the French Armed Forces." About Eutelsat Group Eutelsat Group is a global leader in satellite communications, delivering connectivity and broadcast services worldwide. The Group was formed through the combination of the Company and OneWeb in 2023, becoming the first fully integrated GEO-LEO satellite operator with a fleet of 35 Geostationary satellites and a Low Earth Orbit (LEO) constellation of more than 600 satellites. The Group addresses the needs of customers in four key verticals of Video, where it distributes more than 6,500 television channels, and the high-growth connectivity markets of Mobile Connectivity, Fixed Connectivity, and Government Services. Eutelsat Group's unique suite of in-orbit assets enables it to deliver integrated solutions to meet the needs of global customers. The Company is headquartered in Paris and the Eutelsat Group employs more than 1,500 people across more than 50 countries. The Group is committed to delivering safe, resilient, and environmentally sustainable connectivity to help bridge the digital divide. The Company is listed on the Euronext Paris Stock Exchange (ticker: ETL) and the London Stock Exchange (ticker: ETL). DISCLAIMER The forward-looking statements included herein are for illustrative purposes only and are based on management's views and assumptions as of the date of this document. Such forward-looking statements involve known and unknown risks. For illustrative purposes only, such risks include but are not limited to: risks related to the health crisis; operational risks related to satellite failures or impaired satellite performance, or failure to roll out the deployment plan as planned and within the expected timeframe; risks related to the trend in the satellite telecommunications market resulting from increased competition or technological changes affecting the market; risks related to the international dimension of the Group's customers and activities; risks related to the adoption of international rules on frequency coordination and financial risks related, inter alia, to the financial guarantee granted to the Intergovernmental Organization's closed pension fund, and foreign exchange risk. Eutelsat Communications expressly disclaims any obligation or undertaking to update or revise any projections, forecasts or estimates contained in this document to reflect any change in events, conditions, assumptions, or circumstances on which any such statements are based, unless so required by applicable law. The information contained in this document is not based on historical fact and should not be construed as a guarantee that the facts or data mentioned will occur. This information is based on data, assumptions and estimates that the Group considers as reasonable. View source version on Contacts Media enquiries Joanna DarlingtonTel. +33 674 521 531jdarlington@ Anita BaltagiTel. +33 643 930 178abaltagi@ Katie DowdTel. +1 202 271 2209kdowd@ Investors Joanna DarlingtonTel. +33 674 521 531jdarlington@ Hugo Laurens-BergeTel. +33 670 80 95 58hlaurensberge@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
AV and UAS Denmark Establish Strategic Partnership to Advance Allied UAS Capabilities in Europe
ARLINGTON, Va.--(BUSINESS WIRE)--AeroVironment, Inc. ('AV') (NASDAQ: AVAV) today announced it has signed a Memorandum of Understanding (MOU) with Hans Christian Andersen Aiport in Odense, Denmark–home to the UAS Denmark Test Center–to explore joint utilization of the center's expansive airspace and advanced test facilities. The agreement aims to leverage UAS Denmark's strategic range and infrastructure to support AV's uncrewed aircraft system (UAS) demonstration operations, mission training, and customer integration activities across the region. "Our partnership with UAS Denmark positions us to deliver enhanced capabilities, mission-critical training, and integrated UAS solutions to allied defense forces and government stakeholders across the region." Share The collaboration is expected to enable joint research and development (R&D) initiatives and accelerate the growth of the UAS Denmark Test Center as a regional epicenter for advanced UAS innovation, evaluation, and operational readiness. "This MOU represents a significant milestone in expanding AV's operational footprint in Europe," said Shane Hastings, AV's vice president and general manager of Medium UAS. "Our partnership with UAS Denmark positions us to deliver enhanced capabilities, mission-critical training, and integrated UAS solutions to allied defense forces and government stakeholders across the region." This agreement follows AV's February 2025 Framework Agreement with the Danish Ministry of Defence Acquisition and Logistics Organization (DALO), under which AV is delivering advanced UAS, operator and maintainer training, and lifecycle support to strengthen the Danish Armed Forces' intelligence, surveillance, and reconnaissance (ISR) capabilities. The MOU with UAS Denmark builds on this momentum and reinforces AV's commitment to delivering tactical advantage through scalable, reliable, and combat-proven UAS platforms. By formalizing this collaboration, AV continues to expand its international partnerships and operational support capabilities—ensuring allied forces have access to the tools and training required to maintain readiness in dynamic environments. ABOUT AEROVIRONMENT, INC. AeroVironment ('AV') (NASDAQ: AVAV) is a defense technology leader delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities—built to meet the mission needs of today's warfighter and tomorrow's conflicts. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities with speed, scale, and operational relevance. For more information visit: ABOUT UAS DENMARK TEST CENTER Located at Hans Christian Andersen Airport in Odense, the UAS Denmark Test Center is one of Europe's leading hubs for drone testing, development, and innovation. With access to a dedicated BVLOS airspace, state-of-the-art facilities, and a collaborative ecosystem of government, academia, and industry, the center supports the advancement of cutting-edge unmanned technologies. For more information, visit: SAFE HARBOR STATEMENT Certain statements in this press release may constitute "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, our ability to perform under existing contracts and obtain additional contracts; changes in the regulatory environment; the activities of competitors; failure of the markets in which we operate to grow; failure to expand into new markets; failure to develop new products or integrate new technology with current products; and general economic and business conditions in the United States and elsewhere in the world. For a further list and description of such risks and uncertainties, see the reports we file with the Securities and Exchange Commission. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
an hour ago
- Business Wire
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'company'), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the 'Issuers'), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 ('Notes'). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof. As previously announced, the company is also seeking to partially refinance its credit agreement, whereby the company intends to obtain a $2.325 billion new term B loan facility (the 'New Term B Loan Facility') and a new $800 million revolving credit facility (the 'New Revolving Credit Facility'). The New Term B Loan is expected to accrue interest at a rate of Term SOFR + 4.25% per annum. The allocated size of the New Term B Loan Facility was increased from the previously announced $2.2 billion. The company intends to use the net proceeds from the Notes offering and the New Term B Loan Facility to repay in full the outstanding borrowings under its existing revolving credit facility, to refinance in full its outstanding term A loans due 2027 and term B loans due 2027 and to pay related fees and expenses. The closing of the Notes offering is not contingent upon the closing of the New Term B Loan Facility or the New Revolving Credit Facility. The Notes will be guaranteed by the company and each of the company's subsidiaries (other than the Issuers) that are guarantors under the company's credit agreement and will be secured on a first priority basis by liens on the same assets that secure the obligations under the company's credit agreement and the company's outstanding senior secured notes. Closing of the Notes offering is expected to occur on June 26, 2025, subject to customary closing conditions. The Notes will not be registered under the Securities Act of 1933, as amended ('Securities Act'), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes are being offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. The New Term B Loan Facility and New Revolving Credit Facility are also expected to close on June 26, 2025; however, there can be no assurances that the company will be able to complete the New Term B Loan Facility and/or New Revolving Credit Facility transactions on the terms described above or at all. This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. Forward-looking Statements This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, 'forward-looking statements'), including, but not limited to, our refinancing plans and the details thereof, including the Notes offering, the New Term B Loan Facility and the New Revolving Credit Facility, the proposed use of proceeds therefrom and the details thereof, our ability to complete the transactions described in this press release, and the other expected effects thereof. Forward-looking statements may generally be identified by the use of the words 'anticipates,' 'seeks,' 'expects,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'will,' 'believes,' 'potential,' 'pending' or 'proposed' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators (including the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and its most recent quarterly filings). In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties discussed in such filings will not cause actual results or events to differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2025 Bausch + Lomb.
